Journal: Cell reports

Article Title: Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans

doi: 10.1016/j.celrep.2024.114501

Figure Lengend Snippet: Weight loss efficacy in DIO mice at 22°C and 30°C and in humans living with obesity

Article Snippet: Long acting GDF15 , Novo Nordisk A/S , Cat#NNC-0247-0001-0880.

Techniques:

Journal: Cell reports

Article Title: Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans

doi: 10.1016/j.celrep.2024.114501

Figure Lengend Snippet: Effects on TEE and activity are comparable. (A) Body weight during treatment of male DIO mice with LA-GDF15 (1 nmol/kg s.c. daily). (B) Body weight at day of transfer to the indirect calorimetry system (day −8) and at the end of treatment (day 21). (C and D) Fat mass and fat-free mass at days −8 and 21. (E) TEE during treatment. (F) Change in TEE vs. change in body weight. Changes were calculated by subtracting the values on the last day of treatment from the day before the treatment started. (G) RER (VCO 2 /VO 2 ). (H) Physical activity. Data are mean ± SEM. Biological replicates: n = 8/group. Technical replicates: n = 1. p values compare the difference between days −8 and 21 by two-way ANOVA with uncorrected Fisher’s LSD post hoc testing within Ta or drug treatment. Color scheme: light blue, 22°C vehicle; pink, 30°C vehicle; dark blue, 22°C LA-GDF15; and red, 30°C LA-GDF15.

Article Snippet: Long acting GDF15 , Novo Nordisk A/S , Cat#NNC-0247-0001-0880.

Techniques: Activity Assay

Journal: Cell reports

Article Title: Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans

doi: 10.1016/j.celrep.2024.114501

Figure Lengend Snippet: Primer information

Article Snippet: Long acting GDF15 , Novo Nordisk A/S , Cat#NNC-0247-0001-0880.

Techniques:

Journal: Cell reports

Article Title: Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans

doi: 10.1016/j.celrep.2024.114501

Figure Lengend Snippet:

Article Snippet: Long acting GDF15 , Novo Nordisk A/S , Cat#NNC-0247-0001-0880.

Techniques: Recombinant, Clinical Proteomics, Activity Assay, Expressing, Software

Journal: Journal of drug targeting

Article Title: Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS

doi: 10.3109/10611860903318134

Figure Lengend Snippet: (A) Intranasal delivery in nM of BDNF 25 min after intranasal delivery (N = 7). (B) Intranasal delivery in nM of BDNF 60 min after intranasal delivery (N = 3).

Article Snippet: [ 125 I]-labeled Neurotrophic Factors Recombinant human (rh) BDNF (molecular weight 26,984 Da), NT-4 (22,428 Da), CNTF (22,706 Da), and EPO (glycosylated form 30,400 Da) were each purchased from Cell Sciences, Inc. (Canton, MA, USA).

Techniques:

Journal: Journal of drug targeting

Article Title: Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS

doi: 10.3109/10611860903318134

Figure Lengend Snippet: Concentration of drug 25 min after intranasal delivery in nanograms/mL.

Article Snippet: [ 125 I]-labeled Neurotrophic Factors Recombinant human (rh) BDNF (molecular weight 26,984 Da), NT-4 (22,428 Da), CNTF (22,706 Da), and EPO (glycosylated form 30,400 Da) were each purchased from Cell Sciences, Inc. (Canton, MA, USA).

Techniques: Concentration Assay

Journal: Journal of drug targeting

Article Title: Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS

doi: 10.3109/10611860903318134

Figure Lengend Snippet: Concentration of drug 60 min after intranasal delivery in nanograms/mL.

Article Snippet: [ 125 I]-labeled Neurotrophic Factors Recombinant human (rh) BDNF (molecular weight 26,984 Da), NT-4 (22,428 Da), CNTF (22,706 Da), and EPO (glycosylated form 30,400 Da) were each purchased from Cell Sciences, Inc. (Canton, MA, USA).

Techniques: Concentration Assay

Journal: Journal of drug targeting

Article Title: Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS

doi: 10.3109/10611860903318134

Figure Lengend Snippet: Western blot examination of activation of the pAkt pathway caused by intranasal delivery of either CNTF or BDNF. (A) Representative western blot of control and CNTF-treated occipital cortex 24 and 48 h after a single intranasal application. Control pAkt protein is on the far right. HPRT was used as a loading control. (B) Densitometric examination of relative amounts of pAkt in CNTF-treated occipital cortex 24, 48, 72, and 96 h after a single intranasal application compared to saline-only control cortex (N=6 for each time point). * indicates significantly different from control. (C) Densitometric examination of relative amounts of pAkt in BDNF-treated frontal cortex 24, 48, 72, and 96 h after a single intranasal application compared to saline-only control cortex (N = 6 for each time point). * indicates significantly different from control.

Article Snippet: [ 125 I]-labeled Neurotrophic Factors Recombinant human (rh) BDNF (molecular weight 26,984 Da), NT-4 (22,428 Da), CNTF (22,706 Da), and EPO (glycosylated form 30,400 Da) were each purchased from Cell Sciences, Inc. (Canton, MA, USA).

Techniques: Western Blot, Activation Assay, Control, Saline

Journal: Pharmaceutics

Article Title: In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5, BB-1, and BMP-2) from a PLGA Fiber-Reinforced, Brushite-Forming Calcium Phosphate Cement

doi: 10.3390/pharmaceutics11090455

Figure Lengend Snippet: In vitro release of 2 and 10 µg/mL GDF5 and BB-1 from CPC. Cement discs ( r = 2.0 mm, h = 2.0 mm, V = 25.12 µL) were loaded with 2 or 10 µg/mL GDF5 and BB-1, ground, and incubated at 37 °C in 1 mL of cell culture medium + 10% FCS for 1 h, as well as 1, 2, 3, 6, 8, 10, 13, 15, 17, 20, 22, 28, and 31 days. The release of GDF5 ( A ) and BB-1 ( E ) from ground cement discs was measured by ELISA and used for the calculation of cumulative release ( B , F ), % release ( C , G ), and retention ( D , H ; n = 2).

Article Snippet: The recombinant human (rh) growth factors GDF5 (also called BMP-14), BB-1, and BMP-2 were produced in E. coli by the company BIOPHARM GmbH (Heidelberg, Germany; GDF5, BB-1) and the Hans-Knöll-Institut in Jena (BMP-2) using patented procedures [ ].

Techniques: In Vitro, Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

Journal: Pharmaceutics

Article Title: In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5, BB-1, and BMP-2) from a PLGA Fiber-Reinforced, Brushite-Forming Calcium Phosphate Cement

doi: 10.3390/pharmaceutics11090455

Figure Lengend Snippet: In vitro release of 200 and 1000 µg/mL GDF5 and BB-1 from CPC. Cement cuboids ( l = 10 mm, h = 5.0 mm, w = 5.0 mm, V = 250 µL) were loaded with 200 or 1000 µg/mL GDF5 and BB-1, ground, and incubated at 37 °C in 2 mL of either PBS or sheep serum. After 1 h, as well as 1, 2, 5, 7, 9, 12, 14, 16, 19, 22, 27, and 30 days, the release of GDF5 ( A ) and BB-1 ( E ) from ground cement discs was measured by ELISA and used for the calculation of cumulative release ( B , F ), % release ( C , G ), and retention ( D , H ; n = 1).

Article Snippet: The recombinant human (rh) growth factors GDF5 (also called BMP-14), BB-1, and BMP-2 were produced in E. coli by the company BIOPHARM GmbH (Heidelberg, Germany; GDF5, BB-1) and the Hans-Knöll-Institut in Jena (BMP-2) using patented procedures [ ].

Techniques: In Vitro, Incubation, Enzyme-linked Immunosorbent Assay

Journal: Pharmaceutics

Article Title: In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5, BB-1, and BMP-2) from a PLGA Fiber-Reinforced, Brushite-Forming Calcium Phosphate Cement

doi: 10.3390/pharmaceutics11090455

Figure Lengend Snippet: Release of GDF5, BB-1, and BMP-2 from PLGA fiber-reinforced CPC. Discs consisting of PLGA fiber-reinforced CPC ( r = 4.0 mm, h = 0.5 mm, V = 25.12 µL) were loaded with 400 µg/mL GDF5, BB-1, and BMP-2, ground, and incubated at 37 °C in 1 mL of sheep serum. After 1 h, as well as 1, 3, 7, and 14 days, the release of GDF5 ( A ), BB-1 ( E ), and BMP-2 ( I ) from ground cement discs was measured by ELISA and used for the calculation of cumulative release ( B , F , J ), % release ( C , G , K ), and retention ( D , H , L ). Data are expressed as means ± SEM ( n = 3). * p ≤ 0.05 Mann–Whitney U test vs. pure CPC. + p ≤ 0.05 Mann–Whitney U test vs. 5% fibers.

Article Snippet: The recombinant human (rh) growth factors GDF5 (also called BMP-14), BB-1, and BMP-2 were produced in E. coli by the company BIOPHARM GmbH (Heidelberg, Germany; GDF5, BB-1) and the Hans-Knöll-Institut in Jena (BMP-2) using patented procedures [ ].

Techniques: Incubation, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

Journal: Pharmaceutics

Article Title: In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5, BB-1, and BMP-2) from a PLGA Fiber-Reinforced, Brushite-Forming Calcium Phosphate Cement

doi: 10.3390/pharmaceutics11090455

Figure Lengend Snippet: Differences among the release of the different BMPs from ground pure CPC and CPC ± PLGA fibers (GDF5, BB-1, BMP-2; n = 3 experiments each); # p ≤ 0.05 vs. GDF5; § p ≤ 0.05 vs. BB-1; note: differences among the different release time points are only shown in Figure 3 .

Article Snippet: The recombinant human (rh) growth factors GDF5 (also called BMP-14), BB-1, and BMP-2 were produced in E. coli by the company BIOPHARM GmbH (Heidelberg, Germany; GDF5, BB-1) and the Hans-Knöll-Institut in Jena (BMP-2) using patented procedures [ ].

Techniques:

Journal: Pharmaceutics

Article Title: In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5, BB-1, and BMP-2) from a PLGA Fiber-Reinforced, Brushite-Forming Calcium Phosphate Cement

doi: 10.3390/pharmaceutics11090455

Figure Lengend Snippet: Alkaline phosphatase (ALP) activity in C2C12 cells. C2C12 cells were cultivated for 3 days in diluted extracts of GDF5, BB-1, or BMP-2-containing, ground pure CPC or PLGA fiber-reinforced CPC. Thereafter, the ALP activity was measured using an ALP assay and the data were expressed as fold-change induction compared to the CPC without growth factor; data are expressed as means ± SEM ( n = 3); n.d. = not determined; a.u. = arbitrary units.

Article Snippet: The recombinant human (rh) growth factors GDF5 (also called BMP-14), BB-1, and BMP-2 were produced in E. coli by the company BIOPHARM GmbH (Heidelberg, Germany; GDF5, BB-1) and the Hans-Knöll-Institut in Jena (BMP-2) using patented procedures [ ].

Techniques: Activity Assay, ALP Assay

Journal: Pharmaceutics

Article Title: In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5, BB-1, and BMP-2) from a PLGA Fiber-Reinforced, Brushite-Forming Calcium Phosphate Cement

doi: 10.3390/pharmaceutics11090455

Figure Lengend Snippet: Alkaline phosphatase (ALP) activity in C2C12BRIb cells. C2C12BRIb cells were cultivated for 3 days in diluted extracts of GDF5, BB-1, or BMP-2-containing, ground pure CPC or PLGA fiber-reinforced CPC. Thereafter, the ALP activity was measured using an ALP assay and the data were expressed as fold-change induction compared to the CPC without growth factor; data are expressed as means ± SEM ( n = 3); n.d. = not determined; a.u. = arbitrary units.

Article Snippet: The recombinant human (rh) growth factors GDF5 (also called BMP-14), BB-1, and BMP-2 were produced in E. coli by the company BIOPHARM GmbH (Heidelberg, Germany; GDF5, BB-1) and the Hans-Knöll-Institut in Jena (BMP-2) using patented procedures [ ].

Techniques: Activity Assay, ALP Assay

Journal: Pharmaceutics

Article Title: In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5, BB-1, and BMP-2) from a PLGA Fiber-Reinforced, Brushite-Forming Calcium Phosphate Cement

doi: 10.3390/pharmaceutics11090455

Figure Lengend Snippet: Alkaline phosphatase (ALP) activity in MCHT-1/26 cells. MCHT-1/26 cells were cultivated for 3 days in diluted extracts of GDF5, BB-1, or BMP-2-containing, ground pure CPC or PLGA fiber-reinforced CPC. Thereafter, the ALP activity was measured using an ALP assay and the data were expressed as fold-change induction compared to the CPC without growth factor; data are expressed as means ± SEM ( n = 3); n.d. = not determined; a.u. = arbitrary units.

Article Snippet: The recombinant human (rh) growth factors GDF5 (also called BMP-14), BB-1, and BMP-2 were produced in E. coli by the company BIOPHARM GmbH (Heidelberg, Germany; GDF5, BB-1) and the Hans-Knöll-Institut in Jena (BMP-2) using patented procedures [ ].

Techniques: Activity Assay, ALP Assay

Journal: Pharmaceutics

Article Title: In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5, BB-1, and BMP-2) from a PLGA Fiber-Reinforced, Brushite-Forming Calcium Phosphate Cement

doi: 10.3390/pharmaceutics11090455

Figure Lengend Snippet: Alkaline phosphatase (ALP) activity in ATDC5 cells. ATDC5 cells were cultivated for 3 days in diluted extracts of GDF5, BB-1, or BMP-2-containing, ground pure CPC or PLGA fiber-reinforced CPC. Thereafter, the ALP activity was measured using an ALP assay and the data were expressed as fold-change induction compared to the CPC without growth factor; data are expressed as means ± SEM ( n = 3); n.d. = not determined; a.u. = arbitrary units.

Article Snippet: The recombinant human (rh) growth factors GDF5 (also called BMP-14), BB-1, and BMP-2 were produced in E. coli by the company BIOPHARM GmbH (Heidelberg, Germany; GDF5, BB-1) and the Hans-Knöll-Institut in Jena (BMP-2) using patented procedures [ ].

Techniques: Activity Assay, ALP Assay

Journal: Pharmaceutics

Article Title: In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5, BB-1, and BMP-2) from a PLGA Fiber-Reinforced, Brushite-Forming Calcium Phosphate Cement

doi: 10.3390/pharmaceutics11090455

Figure Lengend Snippet: Effects of GDF5 extracts on the gene expression in hASCs. hASCs were seeded in 12-well plates and exposed for 3 days to the diluted extracts of CPC discs without fibers (CPC) and with 10% ( w / w ) fiber content (CPC+F), the latter either without GDF5 or doped with low dose (10 µg/mL; CPC+F+G) or high dose GDF5 (200 µg/mL; CPC+F+hG). Thereafter, the mRNA expression of Runx2 (RUNX; A ), osterix ( B ), alkaline phosphatase (ALP; C ), type I collagen ( D ), osteopontin ( E ), osteocalcin ( F ), type II collagen ( G ), and aggrecan ( H ) was measured using RT-PCR and the data were expressed as relative expression (as determined using the ΔΔCt method) compared to the CPC without fibers and growth factor; data are expressed as means ± SEM ( n = 8); * p ≤ 0.05 Mann–Whitney U test vs. CPC; # p ≤ 0.05 Mann–Whitney U test vs. CPC+F.

Article Snippet: The recombinant human (rh) growth factors GDF5 (also called BMP-14), BB-1, and BMP-2 were produced in E. coli by the company BIOPHARM GmbH (Heidelberg, Germany; GDF5, BB-1) and the Hans-Knöll-Institut in Jena (BMP-2) using patented procedures [ ].

Techniques: Gene Expression, Expressing, Reverse Transcription Polymerase Chain Reaction, MANN-WHITNEY

Journal: Pharmaceutics

Article Title: In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5, BB-1, and BMP-2) from a PLGA Fiber-Reinforced, Brushite-Forming Calcium Phosphate Cement

doi: 10.3390/pharmaceutics11090455

Figure Lengend Snippet: Effects of GDF5 extracts on the intracellular concentration of collagen 1 protein in hASCs. hASCs were seeded in 12-well plates and exposed for 3 days to the diluted extracts of CPC discs without fibers (CPC) and with 10% ( w / w ) fiber content (CPC+F), the latter either without GDF5 or doped with low dose (10 µg/mL; CPC+F+G) or high dose GDF5 (200 µg/mL; CPC+F+hG). Thereafter, collagen 1 concentrations in cell lysates were quantified using a commercial ELISA kit. The data are expressed as means ± SEM ( n = 8); # p ≤ 0.05 Mann–Whitney U test vs. CPC+F.

Article Snippet: The recombinant human (rh) growth factors GDF5 (also called BMP-14), BB-1, and BMP-2 were produced in E. coli by the company BIOPHARM GmbH (Heidelberg, Germany; GDF5, BB-1) and the Hans-Knöll-Institut in Jena (BMP-2) using patented procedures [ ].

Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY